
Sanofi to replace entire Medivation board to drive sale, according to reports
pharmafile | May 16, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Medivation, Sanofi, replace board, takeover
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it set to propose eight new members to the board.
The current board at Medivation have strongly opposed a sale, claiming that Sanofi’s offer “significantly undervalues” the company. Last week, Sanofi CEO Olivier Brandicourt wrote a letter to the board indicating that they would take steps to remove the board at Medivation if they refused to engage on a potential deal.
Sanofi is set to be receiving advice on their approach to the takeover from Goldman Sachs and Morgan Stanley.
Pfizer are also said to be actively pursuing a deal for Medivation, as they continued to source advice from Goldman Sachs.
To read our feature on why Medivation is so highly sought, please click here.
Sean Murray
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






